Precision medicine has taken another significant leap forward with compelling evidence that targeting specific genetic drivers before cancer spreads could fundamentally alter treatment outcomes for lung cancer patients. This represents a paradigm shift from waiting until advanced stages to deploy targeted therapies.
Selpercatinib, a selective RET kinase inhibitor, demonstrated an 84% objective response rate in patients with early-stage non-small-cell lung cancer harboring RET gene fusions when administered before surgical resection. The phase 2 trial enrolled patients with resectable stage IB-IIIA disease, treating them with neoadjuvant selpercatinib for approximately 12 weeks. Major pathological responses occurred in a substantial portion of participants, with some achieving complete pathological responses where no viable cancer cells remained at surgery.
This finding builds on the established efficacy of RET inhibitors in metastatic disease but extends their application to the curative setting. RET fusions occur in roughly 1-2% of lung adenocarcinomas, typically in younger patients and non-smokers. The high response rates suggest these early-stage tumors may be particularly vulnerable to RET pathway disruption before developing resistance mechanisms.
The study's limitations include its single-arm design without a control group and relatively short follow-up for long-term outcomes. However, the magnitude of responses and the established safety profile of selpercatinib from advanced-stage trials provide strong rationale for this approach. If confirmed in larger randomized trials, neoadjuvant targeted therapy could become standard care for molecularly-defined early-stage cancers, potentially improving cure rates and reducing the need for extensive surgical resections or adjuvant chemotherapy.